The Food and Drug Administration (FDA) has approved Eylea (aflibercept; Regeneron) for the treatment of diabetic retinopathy. The Food and Drug Administration (FDA) has approved Eylea (aflibercept; ...
TARRYTOWN, N.Y. -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that EYLEA ® (aflibercept) Injection has received approval for the treatment of patients with neovascular age-related macular ...
TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and its collaborator Bayer today announced that aflibercept 8 mg and EYLEA® (aflibercept) Injection ...
Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The findings, ...
Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...
TARRYTOWN, N.Y., Nov. 7, 2013 -- /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application for marketing ...
today announced that the U.S. Food and Drug Administration has approved EYLEA Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular Age-related ...
Please provide your email address to receive an email when new articles are posted on . The approval was based on results of the phase 3 PANORAMA trial, which enrolled 402 patients to investigate ...
today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results